The RCVS has launched the Edward Jenner Veterinary Leadership Programme, a online leadership training course for all members of the practice team.

The programme, which was developed in collaboration with the NHS Leadership Academy, is designed to teach a number of skills that underpin good leadership, including decision-making, resilience, implementing an inclusive culture and encouraging reflective learning approaches. It comprises two free-to-access courses and an optional paid for assessment.

The College says that one of the programme's most popular aspects is its audio drama, which follows the lives of veterinary professionals living in the fictional county of Glenvern. The stories that depict the characters’ working lives seek to reveal the diverse leadership challenges that veterinary professionals face on a day-to-day basis. This in turn prompts the listener to reflect, consider how they would respond, and learn from their own experiences as well as those of other people.

The first course was piloted this summer, with over 550 veterinary surgeons, veterinary nurses, students and practice managers helping the College to develop and refine the material, whilst a group of learners are currently piloting the second course in the series.

Simon Patchett MRCVS, who works at Vets Now 24/7 Emergency and Specialty Hospital, Glasgow, said: "This course really highlighted leadership qualities that are often taken for granted. The course demonstrates that you do not need a status position in order to demonstrate effective leadership even though status positions are often where we look for leadership. I would recommend this course to both vets and nurses in clinical practice - it's a real eye opener, and as a result of doing the course perhaps we can see less age-restricted approach to leadership within the veterinary profession?"

Given the overwhelmingly positive feedback received on the first course the RCVS has now opened the programme to all veterinary professionals.

The programme is now accepting registrations for a new cohort of learners to begin the first of three courses on 26^th November.  A ‘sign-up’ email will be sent out to all veterinary surgeons and veterinary nurses ahead of the course starting.

Director of Leadership and Innovation at the RCVS, Anthony Roberts, said: "I am very pleased to be able to announce the launch of this programme. I would urge anyone with an interest in developing their leadership skills, as well as those looking to refine their longstanding leadership skills, to take part. The feedback we have received on the first course in this programme [please see Notes to Editors] has shown us that this MOOC has a far-reaching application, and is both educational and enjoyable. Whether you are a vet, veterinary nurse, practice manager or student, this programme will be relevant and useful in your professional career."

For more information, visit: www.rcvs.org.uk/leadershipmooc or email: leadership@rcvs.org.uk

Yorkshire-based Richard Sutcliffe MRCVS has been suspended for six months after being convicted of common assault, and for conducting surgery and administering POM-V medicine to a person.

The first charge related to his conviction on two counts of common assault by beating two individuals at an incident in December 2016, as a result of which he was made subject to a community order and a restraining order, as well as being fined and made to pay a victim surcharge and costs.

The second charge related to him undertaking, or attempting to undertake non-emergency surgery on the eyelid of one of the individuals referred to in the first charge, and administering, or attempting to administer, a Prescription-Only Veterinary Medicines to the same person. 

The third charged related to an allegation that he had supplied the same individual with a Prescription-Only Medication other than in accordance with a valid prescription.

The second charge and third charges related to incidents which occurred some considerable time before the assault, not as a consequence of it.  

At the outset of the hearing Mr Sutcliffe admitted the first and second charges against him and that these constituted serious professional misconduct. He denied the third charge. In relation to that charge the Committee found that, having considered the totality of the evidence, it was unable to be sure that the College had proved the allegation to the requisite standard of proof, namely so that the Committee was sure. Accordingly Charge 3 was dismissed.

The Committee decided that the convictions in the first charge rendered Mr Sutcliffe unfit to practise veterinary surgery and that his conduct in Charge 2 constituted serious professional misconduct.

The Committee then went on to consider sanction.

The Committee considered the aggravating features for both charges. For the first charge it considered the actual injury to one of his victims and risk of injury to the other, noting also that both of his victims were vulnerable people and one was a child, and that the overall incident during which the assaults occurred lasted over a seven hour period.

For the second charge, aggravating factors were that the non-emergency surgery performed by Mr Sutcliffe was wholly inappropriate, that there was a risk of injury to the individual on whom he performed the surgery and that his conduct was reckless.

The mitigating factors considered by the Committee were that Mr Sutcliffe recognised the gravity of the findings against him and demonstrated insight into the allegations, that the incident in charge 1, though prolonged, was an isolated one, that the incident in charge 2 was consensual and did not result in actual harm and that neither charge had any connection with Mr Sutcliffe’s veterinary practice, nor did they affect client care or animal welfare. 

Professor Alistair Barr, chairing the Committee and speaking on its behalf, said: "As recognised by the Committee, the respondent has displayed insight as to the seriousness of his behaviour. Having regard to the evidence of all the character witnesses and the written testimonials the Committee accepts that the respondent’s conduct as set out in charges 1 and 2 was wholly out of character and, therefore, there is no significant risk of repeat behaviour. The Committee considers that the respondent would be fit to return to practise, having regard to his excellent track record as a veterinary surgeon to date, after any period of suspension.

"Having regards to the aggravating and mitigating factors in this case, the Committee has decided that it is sufficient to maintain public confidence in the profession and declare and uphold proper standards of conduct to give a direction for suspension of the respondent’s name from the Register of Veterinary Surgeons.

"The Committee considers that the period of suspension must be sufficient to mark the seriousness of the charges but must be proportionate and fair in the circumstances of the case. The Committee has therefore concluded that the appropriate period of suspension is six months."

Mr Sutcliffe has 28 days from being informed of the Committee’s decision to appeal to the Privy Council.

Elanco has announced that Onsior 6 mg tablets have been licensed for the treatment of pain and inflammation associated with chronic musculoskeletal disorders in cats.

The NSAID's new indication is in addition to its existing license for acute pain and inflammation.

Elanco points to research it carried out which found that over a six week period, owners saw a visible improvement in their cats' performance of daily activities. There was also a 50% reduction in owner-assessed pain and disability (significantly greater than seen in the placebo group)¹. 

The company says the product, which is administered once-daily as a small flavoured tablet, is well-accepted by most cats, and has a robust safety profile². It is also a winner of an ISFM Easy to Give Award.

Elanco's Veterinary Technical Consultant, Lepha McCartan said: "It is very exciting to be launching this new indication for Onsior because musculoskeletal disorders are commonplace in cats.

"Although reports vary, studies have shown that radiographic evidence of DJD has a prevalence as high as over 90%.³

"At Elanco we are passionate about keeping cats doing what they love and Onsior enables this while also giving vets more choice for managing chronic musculo-skeletal disease."

For more information, visit: myelanco.co.uk or speak to your Elanco territory manager.

References

1. Elanco Animal Health. Data on File: Lascelles BDX, King JN & Archer Thompson NJ (2018) ELA_ONS_Fel_CMSD_PFSS01
2. EPAR – Assessment Report – Variation Elanco Animal Health.
3. Lascelles BDX et al (2010) Cross sectional Study of the prevalence of radiographic DJD in domesticated cats. Vet Surg 2010 39: 535

Veterinary Care for Exotics, the app developed by Mark Rowland, BVSc CertZooMed MRCVS from the Trinity Vet Centre, has had a series of major updates.

The app, which was designed to provide veterinary surgeons, nurses and receptionists with quick access to up-to-date biological data on a wide range of exotic pets, now contains information about 40 different exotic pet species, from Grey Parrots to Sugar Gliders.

Each species entry offers an overview of the pet, details of common conditions, therapeutics and treatment videos. 

Mark, pictured right with a Sulcata tortoise  said: "There are a wide range of exotic pets that are becoming increasingly popular with pet owners, yet very few vets understandably have advanced knowledge in this niche area. The "Veterinary Care for Exotics" app for vets means vets, vet nurses and receptionists can now have this knowledge at their fingertips, giving them the reassuring back-up they need when presented with more unusual pets."

The app can be downloaded from Google Play and from Apple's app store, priced at £11.99.

For more information contact Mark Rowland: trinitycpd@gmail.com. 

The RCVS has announced that it is putting its Westminster headquarters on the market and looking for new premises.

RCVS Council agreed, in principle, to the sale of Belgravia House and for the College and its London-based staff to move to different premises at its November meeting. 

The sale of the building and the move will be overseen by the College’s Estate Strategy Project Board headed by former RCVS President Barry Johnson and including current and former RCVS Council members and RCVS staff.

The RCVS has been based at its current premises in 62-64 Horseferry Road for 25 years, but says it now needs more up-to-date and modern facilities to accommodate a projected increase in the number of staff. 

The College says it has considered a number of alternatives, including expanding the current premises by adding or expanding floors. However, due to the fact that the building is in a conservation area, it has become clear that any such expansions would be unlikely to get planning permission from Westminster Council.

Lizzie Lockett, RCVS Chief Executive, said: "For a number of years it has become apparent that it is fast approaching the time at which our current premises will no longer be fit for purpose due to an increase in the number of RCVS staff – something that is projected to continue in the future – the ongoing need to use the building for Disciplinary Hearings, which take over the lion’s share of available meeting space, and the need for better and more modern facilities.

"Even putting our need for increased space on one side, Belgravia House requires major refurbishment in key areas such as air-conditioning and lifts, which would require staff to vacate the premises for up to 18 months, which would be costly and disruptive.

"We are therefore pleased that Council has recognised the need for the College to move somewhere that better reflects our needs and, over the coming months, we will be exploring a number of different options for new premises.

"In parallel to this we have put out an invitation to tender for agents to manage the sale of the building. The plan is for the arrangement to include lease-back so that we have time to find a suitable premises and enabling us to act quickly when we do."

Any organisations that are interested in putting forward a tender to manage the sale of the building should contact Corrie McCann, RCVS Director of Operations, on 020 7202 0724. Responses to tender are required by 30 November 2018.

Photo: Copyright Google 2018

Pets at Home has announced that following a review of its first opinion veterinary business, it now plans to buy back 55 of the practices it operates in joint venture partnerships with veterinary surgeons, of which 30 may close.

It is thought that the main reason for the cutbacks is a shortage of veterinary surgeons caused by Brexit, which is making it both harder and more expensive to recruit. 

The company has given an undertaking that the joint venture partners of the practices it offers to buy back will not be expected to repay outstanding borrowings to any parties and Pets at Home will settle any liabilities for third party bank loans and leases on behalf of the JVP.

Chief Executive Peter Pritchard said: "Since becoming the Group CEO in May, I have had the opportunity to take stock of the wider group and shape my view of our future.

"What I have found fills me with confidence. Pets at Home is a healthy business and customers are loving what we do; responding to our price repositioning, investment in digital and the amazing service delivered by our vet partners. We have the ability to offer almost everything a pet owner needs, giving us opportunities our competitors simply don't have. Which is why my vision is to develop a complete pet care company, uniting our retail and vet businesses.

"Reviewing our Vet Group has been a priority. I recognise we have grown at pace and more recently, have seen the pressure that rising costs and our fees are placing on this young business. We will need to recalibrate the business to deliver more measured growth, whilst maintaining our plan to generate significant cash profits.

"We are focused on maximising our unique assets and delivering a plan for sustainable cashflow and profit growth. Given the success of the changes we have made in Retail, I'm confident we can do this."

The National Office of Animal Health and the Veterinary Medicines Directorate have issued a joint statement concerning the supply of veterinary medicines when the UK leaves the EU, deal or no deal.

"The majority of veterinary medicines used in the UK (and ingredients and components to make them) are either produced in or enter via the EU. The government is working with animal health companies who have been carrying out extensive contingency planning for all EU Exit scenarios, including no deal. These plans cover all aspects of their supply chains, from regulatory compliance and stocking levels to logistics and customs. They also include, as appropriate, increasing stocks of products in the UK, changing supply routes, transferring marketing authorisations and other regulatory processes. 

"To reduce any risk to medicines availability in the UK, detailed planning is ongoing to ensure that supply chain measures are appropriate to address the sector’s complex needs and priorities.

"Much work has been done by companies with the objective of ensuring fair and appropriate distribution of this inventory to avoid disruption.

"Supply is expected to cope with a normal ordering pattern with adequate forward planning and communication with suppliers.

"With this planning in place, we are confident that we have made every effort to ensure continuity of supply of veterinary medicines in the UK."

Well that makes a nice change from the incessantly and determinedly gloomy picture painted elsewhere.

The Animal Health Trust (AHT) has announced the launch of a new DNA test for the genetic mutation which causes glaucoma in Border Collies.

According to the AHT, glaucoma affects more than a thousand dogs across the UK. Now Border Collie breeders will be able to use this test to reduce the risk of producing glaucoma-affected puppies, whilst maintaining genetic diversity.

The work that resulted in the new test began at the Roslin Institute in Edinburgh, where scientists found a variant in a gene called OLFML3 reported to be associated with severe goniodysgenesis and glaucoma in Border Collies.

On reading this research, the AHT’s canine genetics team, which has an ongoing research programme looking at canine glaucoma, began to look at how a DNA test could be offered based on the mutation.

Hattie Wright, Vets4Pets Research Assistant at the AHT, genotyped a large cohort of Border Collies for the mutation, in order to obtain an accurate measure of the association between the mutation and goniodysgenesis and glaucoma in the Border Collie. These dogs all had their eyes examined, and their DNA collected, by veterinary ophthalmologist James Oliver.

The charity’s findings from this validation process replicated the findings of the Roslin Institute, so the AHT has been able to develop and launch a DNA test based on the reported OLFML3 mutation.

Dr Cathryn Mellersh, Head of Canine Genetics at the Animal Health Trust, said: "We’re delighted to offer this test to Border Collie breeders and hope in time, through its use, we can lessen the prevalence of this disease in this lovely breed.

"Our research has found that the mutation is only associated with glaucoma in Border Collies, so we will publish our data at the earliest opportunity, in the hope that other commercial DNA testing providers will not be tempted to make the DNA test available to breeds other than the Border Collie."

For more information, visit: www.ahtdnatesting.co.uk 

Ceva Animal Health, maker of Adaptil and Feliway, has made March 'Pet Anxiety Month'.

Pet Anxiety Month aims to educate pet owners about the signs of anxiety in cats and dogs, help them identify the causes, and encourage them to take steps to support anxious pets (presumably by putting multiple diffusers in every home and blanketing large swathes of suburbia in a pea soup fog of pheromones).

Joking aside, the initiative comes on the back of the PDSA Animal Wellbeing report¹ which revealed that over half of veterinary professionals think they've seen an increase in dog behavioural issues in the last two years, with over three-quarters of dog owners saying that they would like to change at least one behaviour displayed by their dog and nearly 90% of owners reporting that their cat is afraid of at least one thing.

To support the initiative, Ceva will be running a TV advertising campaign from 7 March until 21 April, which directly targets dog lovers during More4’s Crufts’ programmes (from 7 to 10 March).

The advertisements will also air on Channel 4, Channel 4 partner channels, Sky and Sky partner channels.  Both advertisements are 30 seconds long.

Ceva is producing a marketing pack to raise awareness of Pet Anxiety Month containing eye-catching display materials and a social media toolkit.

Abigail King, Ceva's senior behaviour product manager, said: "More and more people are identifying anxiety and behavioural issues in their pets. Pet Anxiety Month will highlight signs of anxiety in cats and dogs that perhaps an owner is unaware of, help identify the problem and encourage changes both in and out of the home to make the household a happier place."

For further information, visit www.petanxiety.co.uk or Pet Anxiety Month on Instagram or Facebook.

The following small animal medicine dentistry CPD events have been announced for 2019.

If you are speaking at or hosting a small animal CPD event in 2019, please email details to press@vetsurgeon.org for it to be considered for addition to this list.

This list includes events from CPD Solutions, Improve International, the Veterinary Poisons Information Service and the Small Animal Medicine Society.

The RCVS Disciplinary Committee has suspended Dr Jacqueline Bohnen, a South African veterinary surgeon who had been working in the County of Moray, Scotland, for being misleading and dishonest in relation to her treatment of a Cavalier King Charles Spaniel in March 2017.

Dr Bohnen faced two charges. The first was that in March 2017, she failed to attend to Belle, a Cavalier King Charles Spaniel, in order to provide appropriate and adequate care including: assisting Belle with urination, monitoring her with a view to considering alternative treatment options, and monitoring her with a view to providing her owners with an update on her condition.

The second charge was that Dr Bohnen later claimed dishonestly that she had attended to the animal, both to the owners, in clinical records hospital records, in a note provided to colleagues and during internal disciplinary proceedings held at her practice.

At the outset of the hearing the Committee considered an application from Dr Bohnen for the hearing to be postponed as she was now based in her home country of South Africa, and said she could not apply for a visa to return to the UK until later in the year and internet access in her location was poor.

However, the Committee found that the RCVS had properly served the notice of inquiry to Dr Bohnen in accordance with the current rules, that she had had sufficient time and opportunity to apply for a visa since receiving the notice and that, in any case, she could remotely ‘attend’ the hearing via Skype or telephone if necessary by travelling to somewhere that did have adequate internet connectivity, and so it refused the application. 

The Disciplinary Committee then considered the facts of the case and heard evidence from the owners of Belle, the clinical director of the practice that Dr Bohnen worked in at the relevant time and a veterinary nurse, who was a student doing her training at the practice during the time of the events in question.

Having considered all of the evidence, the Committee dismissed the parts of the first charge relating to considering alternative treatment options and updating the owners in relation to Belle’s condition. They did, however, find the charge proven in relation to Dr Bohnen failing to assist Belle with urination.

The Committee found all aspects of the second charge proven in its entirety after Dr Bohnen admitted in advance of the hearing, that her representations were false and misleading.

The Committee then went on to consider whether the second charge and the aspects of the first charge that were found proven amounted to serious professional misconduct both individually and cumulatively.

The Committee considered that Dr Bohnen’s conduct in failing to assist Belle with urination, whilst falling below the standard to be expected of a reasonably competent veterinary surgeon, did not amount to serious professional misconduct. 

The Committee did however find that Dr Bohnen’s conduct with regards to the second charge constituted serious professional misconduct.

Professor Alistair Barr, chairing the Committee and speaking on its behalf, said: "The Committee considers that the respondent’s dishonesty was the prime aggravating factor in this case. Although overall it could be regarded as a single incident, the Committee has found that it involved the fabrication of a number of notes and clinical records in the immediate aftermath of the death of the dog, but, thereafter, the respondent continued to deny the falsity of the fabricated records that she had created up to and until the conclusion of her interview by the practice on 30 March 2017. 

"During that time, the respondent had contacted the alarm company responsible for the security of the premises of the practice, to enquire whether the security system would record the times of the alarm being switched on and off. This indicated that the respondent’s dishonesty continued over a significant period of time, and that her persistence in sticking to her story became premeditated. In other words, the respondent’s conduct over this time indicated a clear attempt to deceive."

Regarding the sanction for Dr Bohnen, the Committee considered that the principle aggravating factors in the case were serious dishonesty towards both her colleagues and the owners of the dog and involved clear breaches of the Code of Professional Conduct. By way of mitigation, the Committee noted that Dr Bohnen is of previous good character with no other professional findings against her and that she had demonstrated some insight into her behaviour and had admitted being dishonest and misleading prior to the hearing. 

Summing up, Professor Barr said: "Because of the seriousness of this case, the Committee did not consider that it was appropriate to postpone judgement, take no further action, or to administer a reprimand and warning as to future conduct. The Committee considered that the respondent’s conduct, involving significant and admitted dishonesty over a period of time, required a significant penalty, in order to protect the welfare of animals and to serve the public interest.

"Accordingly, the Committee has decided to direct that the respondent’s registration be suspended for a period of nine months."

Dr Bohnen has 28 days from being informed of the Committee’s decision to lodge an appeal with the Privy Council.

Whilst you're here, take a moment to see our latest job opportunities for vets.


Virbac has announced the launch of Eradia, the first and only metronidazole for dogs in a flavoured oral suspension.

Suitable for both puppies and adult dogs, Eradia is presented in a bottle with an award-winning¹ 'All-In-One Smart Cap' which stops the person administering the product from coming into contact with the solution, is child proof and offers flexible dosing options.

Available in 30ml and 100ml bottles to cater for all dogs, Eradia can be administered either directly into the mouth or on to food.

Virbac says that Eradia has been shown to be accepted by 100% of dogs², thereby alleviating any possible problems administering metronidazole.



For more information, contact your Virbac Territory Manager.

References

1. Pharma Pack Award 2018. 
2. Nicolas CS, Martins F, Pujol C. Evaluation of palatability of a metronidazole-based oral suspension in dogs when poured on the food and at different stages of shelf-life. In: Proceeding of the 5^th World Congress on Advanced Clinical Trials and Clinical Research. J Clin Trials. 2018;8:45.

Researchers from the University of Melbourne’s Faculty of Veterinary and Agricultural Science, in conjunction with the Waltham Equine Studies Group, have identified a possible mechanistic link between high levels of insulin and equine laminitis.

Their study, which was published in the research journal PeerJ at the end of last year¹, investigated the effects of insulin on equine hoof lamellar cells in the laboratory.

The researchers say that high levels of insulin have been known for some time to cause acute endocrine laminitis, seen when ponies and certain types of horses graze lush pasture or consume a starch- or sugar-rich diet, or when they develop Cushing’s syndrome.

Many ponies and horses at risk of the condition produce large spikes of insulin in their blood stream after consuming meals high in non-structural carbohydrates (in particular starch and simple sugars) which indicates that this could be the way in which they succumb to acute endocrine laminitis.

The mechanism by which insulin can cause effects in the foot leading to laminitis has been the subject of much debate in recent years.

Hormones like insulin must interact with a specific receptor on the surface of cells in order to produce their effects. What has confused researchers in the past is that there appear to be no insulin receptors on the hoof lamellar cells (these cells give the lamellar tissues their strength and changes to their growth or structure weaken the bonds and cause laminitis).

The researchers considered the close similarities between insulin and a growth factor hormone called insulin-like growth factor -1 (IGF-1). There are receptors for IGF-1 on the lamellar cells, and the researchers speculated that high concentrations of insulin might be able to cross-stimulate these cells by activating the IGF-1 receptors. To investigate this possibility PhD student Courtnay Baskerville, together with her supervisor Professor Simon Bailey, developed a method for culturing lamellar epithelial cells in the laboratory, and incubated them with increasing concentrations of insulin.

They found that high concentrations of insulin stimulated the cells to proliferate. Furthermore, this effect could be prevented using an antibody that specifically blocks only the IGF-1 receptor. Further downstream effects within the cells were also shown. The changes seemed to occur mainly at very high concentrations of insulin. Similar concentration levels can be seen in ponies and horses with insulin dysregulation linked to Equine Metabolic Syndrome, but are not commonly seen in normal horses that are considered to be at lower risk of laminitis.

Further work is now ongoing to determine exactly how these cellular changes induced by sustained high insulin concentrations might cause laminitis. However, it seems that targeting the IGF-1 receptor may be an option for developing new drugs to prevent and treat laminitis.

Professor Simon Bailey said: "The information gathered in this study provides the equine industry worldwide with valuable insights into the causes of the common and serious condition of laminitis. The research group would like to acknowledge the support of the Waltham Centre for Pet Nutrition, in particular the involvement of Professor Pat Harris.” 

Reference

1. Baskerville C.L., Chockalingham, S., Harris, P.A., Bailey S.R. (2018). The effect of insulin on equine lamellar basal epithelial cells mediated by the insulin-like growth factor-1 receptor. PeerJ 6:e5945  (DOI 10.7717/peerj.5945).